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Figure 2. Relative expression of FGF1 mRNA under different culture
conditions in co- and mono-cultures of hMSCs and hPCs.
Note: the ﬁrst two authors contributed equally to this work.
Figure 1. A rug-plot of bivariate scatters of ARGS-aggrecan concentrations
in SF, serum, plasma and urine from 36 subjects at different times over 5
years after ACL injury. Concentrations in urine are given corrected for
urinary creatinine. Filled circles are concentrations measured within the
detection limits of the ARGS-aggrecan assay. Open circles are urinary
ARGS concentration below the assay Lower Limit Of Quantiﬁcation (LLOQ;
0.025 pmol/ml) that were imputed to half the LLOQ value. Linear
regression lines (solid) with 95% conﬁdence intervals (long dashed) are
indicted in each scatter plot. In the rug-plot, each bivariate scatter plot
shares information of one variate with the adjacent plot, illustrated by
interconnecting rug fringes showing the marginal distribution of the
shared variate. Horizontal and vertical lines (short dashed) interconnect
ARGS concentrations in different bivariate combinations of ﬂuids in one
subject. All scales are logarithmic and reﬂect the range of ARGS concen-
trations in each ﬂuid.
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ARGS-AGGRECAN QUANTIFICATION IN SYNOVIAL FLUID, SERUM,
PLASMA AND URINE - AN ASSAY VALIDATION
S. Larsson y, S. Lohmander y,z, A. Struglics y. yDept. of Orthopaedics,
Clinical Sci. Lund, Lund Univ., Lund, Sweden; zRes. Unit for
Musculoskeletal Function and Physiotherapy, and Dept. of Orthopaedics
and Traumatology, Univ. of Southern Denmark, Odense, Denmark
Purpose: Aggrecanase cleavage at the 392Glu-393Ala bond in the
interglobular domain of aggrecan, releasing N-terminal 393ARGS
fragments into synovial ﬂuid (SF), is an early key event in arthritis
and joint injuries. We have shown that SF-ARGS is associated with
radiographic progression of knee osteoarthritis (OA) as well as with
progression of self-reported pain after meniscectomy. Our objective
was to validate a modiﬁed ligand-binding assay for the detection of
aggrecanase generated aggrecan fragments with the ARGS neo-
epitope in SF, blood and urine, and to verify the identity of aggrecan
fragments found in blood.
Methods: A sandwich enzyme-linked immunosorbent assay (ELISA) on
the Meso Scale Discovery (MSD) platform for detection of ARGS-
aggrecanwas validated, using a standard made by ADAMTS-4-digestion
of recombinant human aggrecan (1220-PG, R&D Systems), an anti-
aggrecan antibody (AHP0022, Invitrogen) for capture, and amonoclonal
anti-ARGS (OA-1, GlaxoSmithKline) for detection. We analysed recovery
to dilution and spiking of equimolar concentrations of standard in SF
and serum samples. Matched samples of SF, serum, plasma, and urine
were obtained from 36 subjects at different time points 0 to 5 years
after an anterior cruciate ligament (ACL) tear, and analysed for ARGS-
aggrecan content. Aggrecan was puriﬁed by caesium chloride density
gradient centrifugation from serum and plasma pools and analysed by
Western blot using the anti-ARGS antibody. We used Spearman’s rank
order correlation (rS) for assessment of correlation, based on Shapiro-
Wilk test indicating skewed distributions of a majority of the variables.
Results: The limits of quantiﬁcation for the ARGS-aggrecan assay was
between 0.2 and 0.025 pmol ARGS/ml. Inside these limits recovery to
dilution was, mean (range) 100% (83-117%), and to spiking 89% (77-
110%). The sensitivity of the assay was improved 2-fold compared to
when using a standard puriﬁed from human donors. The ARGS con-
centrations were highest in SF (mean, range; 3.02, 0.36 - 30.22 pmol/
ml), 20 times lower in the blood samples (0.14, 0.055 - 0.28 pmol/ml
serum and 0.13, 0.053 - 0.28 pmol/ml plasma), and 80 times lower in
urine (0.036, <0.025 - 0.087 pmol/ml). Serum-ARGS and plasma-ARGS
concentrations were similar, and correlated (Figure 1: rS ¼ 0.773). SFconcentrations correlated with serum and plasma concentrations
(Figure 1: rS ¼ 0.420 and 0.386, respectively). In puriﬁed serum and
plasma samples, we identiﬁed 129-138 kDa aggrecan fragments con-
taining the ARGS neoepitope.Conclusions: This novel ARGS-aggrecan assay is highly sensitive and
suited for analysis of SF and blood samples. Both SF and blood contains
ARGS-aggrecan, and ARGS concentrations in SF and blood are correla-
ted.
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SPECIFIC PEPTIDE DISTRIBUTION IN HUMAN OSTEOARTHRITIC
SYNOVIAL MEMBRANES REVEALS DIFFERENT GRADES OF TISSUE
INFLAMMATION
B. Cillero-Pastor y, G. Eijkel y, F. Blanco z, R. Heeren y. yAMOLF-FOM Inst.,
Amsterdam, Netherlands; zRheumatology Div.. Proteomic Group. Proteo-
Red-ISCIII. INIBIC-Hosp. Univ.rio A Coru~na, A Coru~na, Spain
Purpose: The synovial membrane is an important source for biomarker
discovery of many rheumatic pathologies. The heterogeneity of osteo-
arthritis (OA) affected tissues and the spatial distribution of proteins in
the human synovial membrane is poorly studied. The speciﬁc protein
and peptide proﬁles in different areas of the synovial tissue can reveal
information about the underlying pathways that play a role in the OA
pathology. The distribution of these speciﬁc protein/peptide proﬁles
can be used for tissue/patient classiﬁcation. Matrix assisted laser
desorption ionization mass spectrometric imaging (MALDI-MSI) is a
novel technique that can be employed to reveal the molecular signature
of a region or area of interest in a biological tissue. In this work, we have
studied the peptide proﬁles and their distributions in human normal
and OA synovial membranes.We have described speciﬁc OA biomarkers
commonly found in cartilage and synovial tissues by MALDI-MSI.
Table 1
Positive and negative ion lipid molecular species identiﬁed by MS/MS
m/z peak Lipid assignment Designation
184.0 Phosphocholine [M+H]+
725.5 SM (d18:1/16:0) [M+Na]+
729.5* SM (d18:1/18:1) [M+H]+
739.5 PC (16:0/18:1-N(CH3)3) [M+K]+
741.5 SM (d18:1/16:0) [M+K]+
750.5* PE (18:0/20:4) [M-H]-
756.5* PC (16:0/16:0) [M+Na]+
767.5 SM (d18:1/19:0) or SM(d18:1/18:1) [M+Na]+ or [M+K]+
790.5* PC (18:0/18:0) [M+H]+
798.5 PC (16:0/18:1) [M+K]+
826.6 PC (18:0/18:1) [M+K]+
853.6 SM (d18:1/24:0) [M+K]+
885.6* PI (C18:0/C20:4) [M-H]-
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branes were sectioned in triplicate in 10 mm thick sections and sub-
sequently washed and digested. Microspots of trypsin were deposited by
means of an automatic chemical inkjet printer with high positional
accuracy. Alpha-Cyano-4-hydroxycinnamic acid matrix (HCCA) was
deposited by a vibrational sprayer system. A Synapt HDMSMALDI-Q-TOF
instrumentwasused to perform the imaging-MSandMS/MSexperiments
with a spatial raster size of 150 mm. Principal Component Analysis (PCA)
and discriminant analysis (DA) were used to build regional molecualr
classiﬁers. A Mascot query was performed after MS/MS experiments for
protein identiﬁcation. The location of tryptic peptideswas visualizedwith
Biomap. Hematoxylin-eosin staining and immunohistochemistry studies
validated and complemented the spatial information.
Results: We have studied the peptide distribution in normal and OA
human synovial tissues by MALDI-MSI. By means of PCA and DA we
distinguished OA and normal tissues based on their tryptic peptide
proﬁles. Tryptic peptides from proteins such as hemoglobin subunit
alpha 2 (m/z 1529.8), hemoglobin subunit beta (m/z 952.5, m/z 1126.6,
m/z 1274.7, m/z 1314.7, m/z 1720.0), actin aortic smooth muscle (m/z
1790.9), biglycan (m/z 1312.8) and ﬁbronectin (m/z 1349.7) have been
identiﬁed, for the ﬁrst time to our knowledge, directly from synovial
membrane biopsies. We have determined the localization of OA related
markers such as the heme group, hemoglobin and ﬁbronectin, all of
them co-localized to inﬂamed areas. Biomap software revealed that the
average intensity for group hemewas higher in OA compared to normal
synovial membrane (0,0110,003 vs. 0,0910,029; p<0.05). Fibro-
nectin immunohistochemistry provided complementary validation of
the results obtained by MALDI-MSI. On the other hand, phosphocoline
(m/z 184) was assigned as a marker of OA tissues but localized in areas
of low inﬂammation. Cluster analyses revealed that peaks assigned to
diacylglycerols and actin were molecular signatures speciﬁc to normal
tissues. Finally, we studied common OA peptides analyzing human
synovial and cartilage tissue sections. We have observed that ﬁbro-
nectin and actin related peptides clearly distinguished the diseased
from the normal tissues. Pathway analyses revealed that ﬁbronectin,
hemoglobin and other OA related proteins interacted with integrin
proteins suggesting that this family of proteins has an important role in
the process of cartilage degradation and synovial inﬂammation.
Conclusions: We have classiﬁed normal and OA human synovial
membranes byMALDI-MSI. Peptides exclusively located in areas of high
inﬂammation were identiﬁed revealing disease speciﬁc proﬁles that
contribute to the understanding of OA affected tissues at the molecular
level.
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DIFFERENTIAL LIPID PROFILES OF HUMAN MESENCHYMAL STEM
CELLS UNDERGOING CHONDROGENESIS BY MALDI MASS
SPECTROMETRY IMAGING
B. Rocha y, B. Cillero-Pastor z, G. Eijkel z, C. Ruiz-Romero y,x,
R.A. Heeren z, F.J. Blanco y. yRheumatology Div., Proteomics Group-
ProteoRed/ISCIII, INIBIC-CHUAC, A Coru~na, Spain; zBiomolecular Imaging
Mass Spectrometry (BIMS), FOM Inst. AMOLF, Amsterdam, Netherlands;
xCIBER-BBN, INIBIC-CHUAC, A Coru~na, Spain
Purpose: Recent investigations have argued that there is a close rela-
tionship between altered lipid metabolism and Osteoarthritis (OA)
disease. Mesenchymal stem cells (MSC) are an interesting alternative
for cell-based therapy of cartilage defects due to their capacity to dif-
ferentiate towards chondrocytes in a process called chondrogenesis.
The knowledge of the lipid distribution and modulation during this
process could be used to improve the MSC-based cartilage therapy by
the discovery of new chondrogenic markers. In this study, we have used
matrix-assisted laser desorption/ionization mass spectrometry imaging
(MALDI-MSI) for the characterization of lipids in 3D MSC cultures
(micromasses) at different time points of chondrogenesis.
Methods: MSC micromasses obtained from the bone marrow of 3 OA
donors were collected at day 2 and 14 of chondrogenesis and studied in
duplicate. Samples were cut in sections of 10 mm thickness and dried in
a vacuum desiccator for 20 min to prevent the molecular delocalization.
Two matrix solutions were prepared (Alpha-cyano-4-hydroxycinnamic
acid at 10 mg/ml in 70:30 methanol:triﬂuoroacetic acid 0.2%; 9-Ami-
noacridine at 10 mg/ml in 70:30 ethanol:water) and applied on the
surface of the tissue slides using a vibrational sprayer (ImagePrep,
Bruker, Germany). MALDI-MSI was performed using a MALDI-Q-TOF
instrument (Synapt HDMS, Waters, UK) equipped with a 200-HzNd:YAG laser. Data were acquired in the mass/charge (m/z) range of
100-1000 and at a raster size of 100 mm (positive and negative V-
reﬂectron mode). Ion images were generated with Biomap 3.7.5.5
software. Principal component analysis (PCA) and discriminant analysis
(DA) were used to look for the masses with the highest differences
between all samples studied. Finally, tandem mass spectrometry (MS/
MS) was carried out to identify these masses. Lipid assignments were
performed according to literature and LIPID MAPS Structure Database
(LMSD).
Results: MALDI-MSI revealed a differential lipid proﬁle between the
two time points (2 and 14 days). Firstly, we analyzed the lipid compo-
sition in the positive mode. The analysis of 683 spectra by statistical
methods such as PCA and DA showed a higher lipid content at day 2 of
chondrogenesis. According to Lipidmaps database and MS/MS frag-
mentation, these peaks are attributed to phosphocholine (m/z 184) and
several phosphatidylcholines (PC) (m/z 739.5, m/z 798.5 andm/z 826.6)
(Table 1). Other differentially expressed peaks could be assigned to
sphingomyelines (SM) (m/z 725.5, m/z 741.5, m/z 767.5 and m/z 826.6).
Only m/z 729.5, m/z 756.5 and m/z 790.5 were increased at day 14,
corresponding to SM and two PCs, respectively. For the negative mode
745 spectra were used. The ﬁrst discriminant function revealed a high
presence of phosphatidylinositols (PI) (m/z 885.6) and phosphatidyle-
tanolamines (PE) such as m/z 750.5 speciﬁcally at day 14. Biomap
software conﬁrmed the results obtained by PCA and DA (Figure 1).
Conclusions: These data demonstrate that MALDI-MSI can be used for
the identiﬁcation of putative chondrogenic markers. We have observed
that the lipid metabolism is involved in the chondrogenic process.
Phosphatidyletanolamine and phosphatidylinositol pathways are
increased in chondrocyte-differentiated MSC, whereas phosphocho-
line-related lipids could be markers of the undifferentiated stage.75
PHYSICAL THERAPY FOR HIP OSTEOARTHRITIS: RANDOMISED,
PLACEBO-CONTROLLED TRIAL
K.L. Bennell y, T. Egerton y, J. Martin y, J.H. Abbott z, B. Metcalf y,
F. McManus y, K. Sims x, Y.-H. Pua k, T.V. Wrigley y, A. Forbes{,
C. Smith{, A. Harris #, R. Buchbinder yy. yCtr. for Hlth., Exercise & Sports
Med., University of Melbourne, Australia; zCtr. for Musculoskeletal
Outcomes Res., University of Otago, New Zealand; xCricket Australia Ctr.
of Excellence, Brisbane, Australia; kDept. of Physiotherapy, Singapore
